Cellectar Biosciences (CLRB) said late Wednesday it closed a public offering of units for gross proceeds of about $6.9 million.
The offering included over 1 million class A units priced at $5 each, comprising one common share and one warrant to purchase a common share. That total includes 180,000 class A units issued following the full exercise of the underwriters' overallotment option.
Cellectar also sold 335,000 class B units at $4.99999 each, with each unit consisting of a pre-funded warrant to buy one common share and one common warrant.
The company said it plans to use the net proceeds for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.